Inventor · disambiguated record
Andrew Tustian
Also filed as: TUSTIAN ANDREW · TUSTIAN ANDREW DAVID
19 granted patents·14 pending applications·115 citations·filing 2015–2025
95Inventor score
Files withREGENERON PHARMA33
Top patents by PatentIndex Score
33 records- 0198US11459373B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2021·Granted Oct 4, 2022·8 cites·16 claims
- 0298US11459374B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Oct 4, 2022·13 cites·26 claims
- 0398US11299532B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2021·Granted Apr 12, 2022·8 cites·22 claims
- 0498US11174283B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2021·Granted Nov 16, 2021·13 cites·12 claims
- 0598US11053280B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2020·Granted Jul 6, 2021·19 cites·11 claims
- 0697US12049489B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2023·Granted Jul 30, 2024·2 cites·30 claims
- 0797US11649273B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted May 16, 2023·2 cites·28 claims
- 0897US11407813B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2021·Granted Aug 9, 2022·3 cites·20 claims
- 0994US12202883B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2024·Granted Jan 21, 2025·0 cites·12 claims
- 1094US11505594B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Nov 22, 2022·1 cites·27 claims
- 1194US11180540B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2020·Granted Nov 23, 2021·2 cites·28 claims
- 1294US10626142B2Purification platform for bispecific antibodiesREGENERON PHARMA·Filed 2015·Granted Apr 21, 2020·34 cites·40 claims
- 1394US2025197474A1Anti-vegf protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1491US11286290B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2021·Granted Mar 29, 2022·1 cites·30 claims
- 1590US12077570B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2023·Granted Sep 3, 2024·0 cites·30 claims
- 1688US11098112B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2020·Granted Aug 24, 2021·1 cites·26 claims
- 1787US12054533B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Aug 6, 2024·0 cites·18 claims
- 1887US11358984B2Use of Raman spectroscopy in downstream purificationREGENERON PHARMA·Filed 2019·Granted Jun 14, 2022·4 cites·41 claims
- 1986US12152056B2Method and chromatography system for determining amount and purity of a multimeric proteinREGENERON PHARMA·Filed 2019·Granted Nov 26, 2024·4 cites·6 claims
- 2082US2023348532A1Manufacturing process for high titer antibodyREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2182US2023331776A1Manufacturing process for high titer antibodyREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2282US2023332084A1Bioreactor for antibody productionREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2382US2023287043A1Cell culture methods for antibody productionREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2482US2023332201A1Cell culture methods for antibody productionREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2582US2024010737A1Manufacturing process for high titer antibodyREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2681US2025361266A1Use of raman spectroscopy in downstream purificationREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2775US12398176B2Use of Raman spectroscopy in downstream purificationREGENERON PHARMA·Filed 2022·Granted Aug 26, 2025·0 cites·29 claims
- 2867US2025163468A1Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virusREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2967US2023257719A1Production of High Titer Recombinant Vesicular Stomatitis Virus in Suspension Cell CultureREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3062US2025122482A1Production and purification of covalently surface modified adeno-associated virusREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3158US2024425825A1Methods for purifying filled adeno-associated virus capsidsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3254US2023063116A1Vegf mini-traps and method of use thereofREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 3335US2017191101A1Clarification of mammalian cell cultureREGENERON PHARMA·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Andrew Tustian files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →